Compare ResMed Inc. (RMD) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Texas Instruments Incorporated — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Texas Instruments Incorporated trades at $260.77 (market cap $236.46B). The key difference: Texas Instruments Incorporated is far larger — about 7.4× ResMed Inc.'s market cap, and Texas Instruments Incorporated pays the higher dividend (2.19%). Which is the better fit depends on your goals.
| RMD | TXN | |
|---|---|---|
Market Cap | $31.89B | $236.46B |
Sector | Health | Technology |
52-Week High | $283.28 | $332.35 |
52-Week Low | $182.82 | $153.33 |
Enterprise Value | $31.24B | $243.51B |
Dividend Yield | 1.19% | 2.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
Texas Instruments (TXN) trades at $261.59, up 1.22% with a bearish technical signal. The company reported mixed Q4 2025 earnings but beat expectations in Q1 and Q2 2026. Revenue growth is recovering from 2024 lows, with 2025 revenue at $17.68B and net income of $5.00B. Analyst consensus is bullish with a $329.74 price target, though technical indicators show resistance near $262.
The outlook remains positive with strong profitability margins and AI-driven demand, but risks include rising debt levels and competitive pressures. The stock offers potential upside from current levels if earnings momentum continues, supported by institutional buy ratings and strategic positioning in analog chips.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
